A Randomized Controlled Trial Comparing the TruSteer and FXD Double Curve Delivery Systems for Left Atrial Appendage Occlusion With the Watchman FLX Pro Device-The GUIDE-LAAO Study.

Catheter Cardiovasc IntervJul 6, 2026 (epub)
Clinical ResearchCardiologyCardiothoracic SurgeryOpen access

Philippe Taieb, Marco Frazzetto, Pedro Soares Teixeira et al.

✦ AI-curated · Sources linked

In 30 seconds

The GUIDE-LAAO trial assessed the TruSteer deflectable delivery system against the FXD Double Curve system for left atrial appendage occlusion in 50 patients with non-valvular atrial fibrillation. Procedural success was achieved in 100% of TruSteer patients compared to 84% for FXD DC, demonstrating non-inferiority (risk difference 16%; 95% CI -6.9% to 34.7%).

Key findings

  • Procedural success was 100% for TruSteer vs 84% for FXD DC.
  • Technical and device success rates were both 100% for TruSteer and 92% for FXD DC.
  • Periprocedural complications occurred in 4% of TruSteer patients and 16% of FXD DC patients.

Why it matters

This study provides evidence that deflectable delivery systems like TruSteer can achieve high procedural success rates in left atrial appendage occlusion, potentially improving outcomes in patients with atrial fibrillation.

Source

PubMed · PMID 42403266Free full text on PubMed Central

Published in Catheter Cardiovasc Interv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.